A Single Center, Prospective, Case Series of the Treatment of Pressure Ulcers and Decubitus Ulcers.

Pressure Ulcer Clinical Trial

Official title:

A Case Series to Investigate the Safety and Efficacy of Weekly Application of Dehydrated Human Amnion/Chorion Membrane in the Treatment of Pressure Ulcers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03529578
• Other study ID #: EFPU002
• Status: Completed
• Phase: N/A
• Start date: June 6, 2017
• Est. completion date: June 1, 2019

Study information

• Verified date: November 2020
• Source: MiMedx Group, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the efficacy and safety of dehydrated amnion/chorion membrane (dHACM) in the treatment of patients with stage II or III pressure ulcer and decubitus ulcers

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 1, 2019
• Est. primary completion date: June 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Index ulcer characteristics:

1. Index ulcer area after debridement is = 2 cm² and = 25 cm² at the randomization visit

2. Ulcer must be Stage II or III as determined by the National Pressure Ulcer Advisory Panel (NPUAP) pressure ulcer staging system

2. Subject criteria must include:

1. Age 18 or older

2. The subject or their legally authorized representative provides consent and is willing and able to participate in all procedures and follow-up evaluations necessary to complete the study

Exclusion Criteria:

1. Index ulcer characteristics that will make subject ineligible for enrollment:

1. Stage I or IV ulcers as determined by NPUAP pressure ulcer staging system

2. Signs and symptoms of local infection

3. Previous surgical procedure performed at site

4. Known or suspected local skin malignancy at index ulcer site

5. Prior radiation therapy treatment at the index ulcer site

2. Subject criteria that will make subject ineligible for enrollment:

1. Presence of other diseases which, in the Opinion of the Investigator, may result in allograft failure or has experienced graft failure in the past (examples include: immune system disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired Immunodeficiency Syndrome (AIDS) or HIV)

2. Currently taking medications which in the opinion of the investigator may affect graft incorporation

3. Allergy or known sensitivity to Aminoglycosides such as gentamicin sulfate and/or streptomycin sulfate

4. Any condition(s) that in the opinion of the investigator may seriously compromises the subject's ability to participate in this study. Examples include: known history of poor adherence with medical treatment, current drug or alcohol abuse or a medical/psychiatric condition

5. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence)

6. Subjects currently enrolled in this study (i.e. concurrent enrollment in the study is prohibited)

7. Subject has used any investigational drug(s) or therapeutic device(s) within 30 days preceding screening.

8. Any pathology that would limit the blood supply and compromise healing

9. Subject is a prisoner

Related Conditions & MeSH terms

• Pressure Ulcer
• Ulcer

Intervention

Procedure:
• dHACM
Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)

Locations

Country	Name	City	State
United States	Infectious Disease Specialists of Atlanta, PC	Decatur	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
MiMedx Group, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Comparison of Quality of Life for subjects [Exploratory]	Comparison of Quality of Life for subjects after treatment; This data will be measured by the SF-12 Health Survey at three time points throughout the study (8 weeks): prior to treatment, at 4 weeks, and at the end of the trial.	8 weeks
Primary	Percentage of subjects with complete wound closure of study ulcer	The percentage of subjects with complete wound closure of the study ulcer	8 Weeks
Secondary	Wound healing kinetics: Complete wound healing	Total time for complete wound healing	8 weeks
Secondary	Wound healing kinetics: Weekly percentage of wounds with total closure	Percentage of wounds with total closure at each weekly visit time point	8 weeks
Secondary	Wound healing kinetics: rate of closure/week	Rate of wound closure/week	8 weeks
Secondary	Incidence of Treatment-Emergent Adverse Events [Safety]	The endpoints for safety will be reported as the frequencies of occurrence of each adverse event, the rate of adverse events per patient/month and time to each event; Both serious and non-serious adverse events will be recorded	8 weeks
Secondary	Wound Infection Rate [Safety]	Additionally, wound infection rates will be noted throughout the course of the study	8 weeks